FibroGen, Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction on Tuesday, February 14th. The shares were sold at an average price of $23.94, for a total transaction of $924,945.84. Following the sale, the chief executive officer now directly owns 3,274,061 shares of the company’s stock, valued at approximately $78,381,020.34. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

FibroGen, Inc (NASDAQ:FGEN) opened at 24.40 on Friday. FibroGen, Inc has a 1-year low of $14.50 and a 1-year high of $25.70. The stock’s market cap is $1.54 billion. The company’s 50 day moving average is $23.66 and its 200-day moving average is $20.68.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

This report was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this report can be accessed at http://www.dailypolitical.com/2017/02/17/thomas-b-neff-sells-38636-shares-of-fibrogen-inc-fgen-stock.html.

A number of research firms recently weighed in on FGEN. Zacks Investment Research upgraded shares of FibroGen from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Friday, January 20th. RBC Capital Markets restated a “buy” rating on shares of FibroGen in a research note on Wednesday, January 18th. Stifel Nicolaus restated a “positive” rating and set a $33.00 target price on shares of FibroGen in a research note on Wednesday, January 18th. Finally, Leerink Swann restated a “buy” rating and set a $52.00 target price on shares of FibroGen in a research note on Wednesday, November 9th. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average target price of $36.20.

A number of large investors have recently bought and sold shares of FGEN. TLP Group LLC purchased a new stake in FibroGen during the third quarter worth approximately $108,000. Teacher Retirement System of Texas boosted its position in FibroGen by 15.7% in the second quarter. Teacher Retirement System of Texas now owns 6,891 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 937 shares in the last quarter. Stifel Financial Corp bought a new position in FibroGen during the second quarter worth about $243,000. SG Americas Securities LLC bought a new position in FibroGen during the third quarter worth about $246,000. Finally, Fox Run Management L.L.C. boosted its position in FibroGen by 15.0% in the third quarter. Fox Run Management L.L.C. now owns 12,300 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 1,600 shares in the last quarter. 47.74% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.